100% Quality Guarantee
PhD-Level Technical Support
Rat VEGFA Recombinant Protein (N-His)
Key Features

Rat VEGFA Recombinant Protein (N-His) (GXRP06113)

SKU GXRP06113
Product Type Recombinant Protein
Species Rat
Expression System E. coli
Tag N-His
$458 - $2,412

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Rat VEGFA Recombinant Protein (N-His)

Rat VEGFA Recombinant Protein (N-His) is a recombinant protein expressed in E. coli, spanning Ala27-Arg214, with an N-terminal His tag. Predicted molecular weight: 24.37 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. Vascular endothelial growth factor A (VEGFA) is a ~25 kDa protein. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. For research use only.

Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. May play a role in increasing vascular permeability during lactation, when increased transport of molecules from the blood is required for efficient milk protein synthesis. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. VEGFA is the therapeutic target of bevacizumab (Avastin).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose